Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices

Data de publicação:

Autores da FMUP

  • Daniel Humberto Pozza

    Autor

Participantes de fora da FMUP

  • Roque, K
  • Ruiz, R
  • Mas, L
  • Vancini, M
  • Silva, JA Jr
  • de Mello, RA

Unidades de investigação

Abstract

Simple Summary Immunotherapy stands as a cornerstone in the treatment of advanced lung cancer patients without an oncogenic driver mutation. This comprehensive review provides an overview of immunotherapy treatment options and offers an algorithm for selecting the most appropriate regimen in various clinical scenarios. Additionally, we delve into practical considerations commonly encountered in clinical settings, as well as the latest advancements in the field.Abstract The introduction of immunotherapy has brought about a paradigm shift in the management of advanced non-small cell lung cancer (NSCLC). It has not only significantly improved the prognosis of patients but has also become a cornerstone of treatment, particularly in those without oncogenic driver mutations. Immune checkpoint inhibitors (ICIs) play a crucial role in the treatment of lung cancer and can be classified into two main groups: Anti-cytotoxic T lymphocyte antigen-4 (Anti-CTLA-4) and anti-T-cell receptor programmed cell death-1 or its ligand (Anti-PD-1 and Anti-PD-L1). Certainly, the landscape of approved first line immunotherapeutic approaches has expanded to encompass monotherapy, immunotherapy-exclusive protocols, and combinations with chemotherapy. The complexity of decision-making in this realm arises due to the absence of direct prospective comparisons. However, a thorough analysis of the long-term efficacy and safety data derived from pivotal clinical trials can offer valuable insights into optimizing treatment for different patient subsets. Moreover, ongoing research is investigating emerging biomarkers and innovative therapeutic strategies that could potentially refine the current treatment approach even further. In this comprehensive review, our aim is to highlight the latest advances in immunotherapy for advanced NSCLC, including the mechanisms of action, efficacy, safety profiles, and clinical significance of ICI.

Dados da publicação

ISSN/ISSNe:
2072-6694, 2072-6694

Cancers  Multidisciplinary Digital Publishing Institute (MDPI)

Tipo:
Review
Páginas:
4547-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Scopus: 8

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • immune checkpoint inhibitors (ICIs); non-small cell lung cancer (NSCLC); PD-1; PD-L1; CTLA-4; oncogenic driver mutation; treatment sequencing; tumour biomarkers; personalized medicine

Financiamento

Proyectos asociados

Resultados de um Protocolo QST em voluntários saudáveis e em pacientes com dor crónica: um ensaio clínico controlado

Investigador Principal: Daniel Humberto Pozza

Ensaio Clínico Académico (Dor Crónica) . 2023

Citar a publicação

Partilhar a publicação